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Abstract
Background & Aims: Genome-wide association studies identified the autophagy gene IRGM to be strongly associated with
Crohn’s disease (CD) but its impact in ulcerative colitis (UC), its phenotypic effects and potential epistatic interactions with
other IBD susceptibility genes are less clear which we therefore analyzed in this study.
Methodology/Principal Findings: Genomic DNA from 2060 individuals including 817 CD patients, 283 UC patients, and 961
healthy, unrelated controls (all of Caucasian origin) was analyzed for six IRGM single nucleotide polymorphisms (SNPs)
(rs13371189, rs10065172 =p.Leu105Leu, rs4958847, rs1000113, rs11747270, rs931058). In all patients, a detailed genotype-
phenotype analysis and testing for epistasis with the three major CD susceptibility genes NOD2, IL23R and ATG16L1 were
performed. Our analysis revealed an association of the IRGM SNPs rs13371189 (p = 0.02, OR 1.31 [95% CI 1.05–1.65]),
rs10065172 =p.Leu105Leu (p = 0.016, OR 1.33 [95% CI 1.06–1.66]) and rs1000113 (p = 0.047, OR 1.27 [95% CI 1.01–1.61]) with
CD susceptibility. There was linkage disequilibrium between these three IRGM SNPs. In UC, several IRGM haplotypes were
weakly associated with UC susceptibility (p,0.05). Genotype-phenotype analysis revealed no significant associations with a
specific IBD phenotype or ileal CD involvement. There was evidence for weak gene-gene-interaction between several SNPs
of the autophagy genes IRGM and ATG16L1 (p,0.05), which, however, did not remain significant after Bonferroni correction.
Conclusions/Significance: Our results confirm IRGM as susceptibility gene for CD in the German population, supporting a
role for the autophagy genes IRGM and ATG16L1 in the pathogenesis of CD.
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Introduction
Crohn’s disease (CD) and ulcerative colitis (UC) are chronic
inflammatory bowel diseases (IBD) resulting from an inappropriate
immune response to microbial antigens in genetically susceptible
individuals [1,2,3,4]. Recent genome-wide association studies
(GWAS) have provided valuable insights into the genetic
architecture particularly of CD, identifying more than 70 CD
susceptibility variants with the most significant findings in the gene
regions of NOD2, IL23R and ATG16L1 [5,6,7,8,9]. These genetic
findings confirm an important role for innate immunity, proin-
flammatory IL-23/Th17 immune responses as well as autophagy
for both gut homeostasis and the development of chronic
inflammation in IBD.
In addition to the CD susceptibility gene ATG16L1 involved in
autophagy [9,10,11], recent GWAS identified the single nucleotide
polymorphism (SNP) rs13361189 – a SNP lying immediately
upstream of the autophagy gene IRGM (immunity-related GTPase
family M) – and other IRGM SNPs to be strongly associated with
CD [12,13]. Since the discovery of the IRGM as a CD
susceptibility gene, further studies have investigated IRGM gene
variants in both adult and pediatric CD
[14,15,16,17,18,19,20,21,22] as well as in UC [14], confirming
its role in the IBD pathogenesis.
A functional study suggested a common, 20-kb deletion
polymorphism upstream of IRGM, which is in perfect linkage
disequilibrium (LD) with rs13361189, as a likely causal variant,
since the deletion allele modulated the expression of IRGM in
transformed cells [22]. Another recent study implicated a variant
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in the 59-untranslated region (2308(GTTT)5) to be independently
associated with CD [20], while the very recent study by Brest et al.
[21] demonstrated functional effects of the synonymous SNP
rs10065172 (c.313C.T), which is also in linkage disequilibrium
with rs13361189 and the deletion polymorphism. This exonic,
synonymous variant rs10065172 in IRGM alters a binding site for
certain microRNAs (miR-196) and causes deregulation of IRGM-
dependent xenophagy of bacteria in patients with CD [21],
therefore suggesting rs10065172 as disease-causing variant.
These studies implicate that autophagy plays an important role
in human inflammatory disorders by direct elimination of
intracellular bacteria and activation of pattern recognition
receptor (PRR) signaling which is involved in gut homeostasis
and CD pathogenesis [10,23]. The IRGM gene belongs to
immunity-related GTPases (IRG), a family of genes in mammalian
species induced by interferons (IFNs) and functioning as key
mediators of IFN-regulated resistance to intracellular bacteria and
protozoa [23]. IRGM has been shown to play a role in the
autophagy-targeted destruction of Mycobacterium bovis BCG [23]
and the IFN-c-induced host defense against Salmonella typhimurium
infection [10]. Interestingly, a recent study in CD patients
demonstrated that autophagy limits the replication of intracellular
adherent-invasive Escherichia coli (AIEC) associated with ileal CD
and that IRGM- and ATG16L1-deficient cells had enhanced
intracellular AIEC bacteria replication, suggesting a significant
impact on the outcome of intestinal inflammation [24].
While several GWAS and replication studies established IRGM
as a CD susceptibility gene, its effects on the IBD phenotype are
less clear. In addition, epistatic interactions with other IBD
susceptibility genes, in particular the second autophagy gene
ATG16L1, have not been studied in detail. Therefore, in this study,
we aimed to analyze the role of IRGM on CD and UC
susceptibility as well as its effect on the IBD phenotype in a large
patient-control cohort. In addition, we performed a detailed
epistasis analysis of IRGM with the three major CD susceptibility
genes NOD2, ATG16L1 and IL23R. In total, six major IRGM
SNPs, for which associations with CD were shown in previous
studies (see details in Methods), were genotyped in more than 2000
German IBD patients and controls.
Patients and Methods
Ethics statement
The study was approved by the Ethics committee of the Medical
Faculty of the Ludwig-Maximilians-University Munich. Written,
informed consent was obtained from all patients prior to the study.
Study protocols were based on the ethical principles for medical
research involving human subjects of the Helsinki Declaration
(http://www.wma.net/e/policy/b3.htm).
Study population and definition of IBD phenotype
The study population (n= 2060) consisted of 1099 IBD patients
including 817 patients with CD, 283 patients with UC, and 961
healthy, unrelated controls, all of Caucasian origin. Patient charts
were analyzed for demographic and clinical parameters (disease
behaviour and anatomic location of IBD, disease-related compli-
cations, history of surgery or immunosuppressive therapy) and all
patients participated in a detailed questionnaire including an
interview at time of enrolment. The diagnosis of CD or UC was
determined according to endoscopic, histopathologic and radio-
logical criteria of current international guidelines [25]. Patients
with clinical features of both CD and UC (and therefore classified
as ‘‘indeterminate colitis’’) were excluded from this study. Patients
with CD were assessed based on the Montreal classification
including age at diagnosis (A), location (L), and behaviour (B) of
disease [26]. In patients with UC, anatomic location was also
assessed following the Montreal classification analyzing the criteria
ulcerative proctitis (E1), left-sided UC (distal UC; E2), and
extensive UC (pancolitis; E3) [26]. The demographic baseline
characteristics of the study population were collected blind to the
results of the genotype analyses and are summarized in Table 1.
Table 1. Demographic characteristics of the IBD study population.
Crohn’s disease Ulcerative colitis Controls
n= 817 n= 283 n= 961
Gender
Male (%) 46.0 53.0 63.6
Female (%) 54.0 47.0 36.4
Age (yrs)
Mean 6 SD 40.7613.3 43.8614.4 47.369.06
Range 15–81 16–88 19–68
Body mass index
Mean 6 SD 23.064.2 23.964.5
Range 13–41 15–54
Age at diagnosis (yrs)
Mean 6 SD 27.9612.0 31.3613.7
Range 6–78 4–81
Disease duration (yrs)
Mean 6 SD 13.168.8 11.968.4
Range 0–46 1–50
Positive family history of IBD (%) 16.7 17.4
doi:10.1371/journal.pone.0054338.t001
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DNA extraction
From all study participants, blood samples were taken and
genomic DNA was isolated from peripheral blood leukocytes using
the DNA blood mini kit from Qiagen (Hilden, Germany)
according to the manufacturer’s guidelines.
Genotyping of the IRGM variants
Six IRGM SNPs (rs13361189, rs10065172= pLeu105Leu,
rs4958847, rs1000113, rs931058, rs11747270) were genotyped.
The selection of these six IRGM SNPs was based on previous
studies showing associations for these SNPs in large case-control
cohorts. The SNPs rs13361189, rs10065172= p.Leu105Leu and
rs4958847 were selected from the study of Parkes et al. [12], while
the SNPs rs1000113 and rs931058 were tested in the study of the
Wellcome Trust Case Control Consortium (WTCCC) [13]. The
SNPs rs13361189 and rs10065172= p.Leu105Leu served also as
proxies for a common, 20-kb deletion polymorphism upstream of
IRGM, since they are in perfect linkage disequilibrium (r2 = 1.0)
with this deletion polymorphism [22]. Additionally rs11747270,
which was the most strongly CD-associated SNP within the IRGM
region in the meta-analysis of Barrett et al., was included.
IRGM genotyping was performed by PCR and melting curve
analysis using a pair of fluorescence resonance energy transfer
(FRET) probes in a LightCyclerH 480 Instrument (Roche
Diagnostics, Mannheim, Germany) as previously described in
detail [27,28,29,30,31]. The donor fluorescent molecule (fluores-
cein) at the 39-end of the sensor probe is excited at its specific
fluorescence excitation wavelength (533 nm) and the energy is
transferred to the acceptor fluorescent molecule at the 59-end
(LightCycler Red 610, 640 or 670) of the anchor probe. The
specific fluorescence signal emitted by the acceptor molecule is
detected by the optical unit of the LightCycler 480 instrument.
The sensor probe is exactly matching to one allele of each SNP,
preferentially to the rarer allele, whereas in the case of the other
allele there is a mismatch resulting in a lower melting temperature.
The total volume of the PCR was 5 ml containing 25 ng of
genomic DNA, 16 Light Cycler 480 Genotyping Master (Roche
Diagnostics), 2.5 pmol of each primer and 0.75 pmol of each
FRET probe (TIB MOLBIOL, Berlin, Germany). In the case of
rs11747270, the amount of the forward primer was reduced to one
fifth and in the case of rs4958847 the reverse primer was reduced
to one half. In the case of rs10065172 and rs931058, the reverse
primers were reduced to one third, respectively. The PCR
comprised an initial denaturation step (95uC for 10 min) and 45
cycles (50 cycles in the case of rs10065172) [95uC for 10uC sec,
60uC (55uC in the case of rs10065172) for 10 sec, 72uC for
15 sec]. The melting curve analysis comprised an initial denatur-
ation step (95uC for 1 min), a step rapidly lowering the
temperature to 40uC and holding for 2 min, and a heating step
slowly (1 acquisition/uC) increasing the temperature up to 95uC
and continuously measuring the fluorescence intensity. The results
of melting curve analysis have been confirmed by analyzing two
patient samples for each possible genotype using sequence analysis.
For sequencing, the total volume of the PCR was 100 ml
containing 250 ng of genomic DNA, 16 PCR buffer (Qiagen,
Hilden, Germany), a final MgCl2 concentration of 2 mM, 0.5 mM
of a dNTP mix (Sigma, Steinheim, Germany), 2.5 units of HotStar
Plus TaqTM DNA polymerase (Qiagen) and 10 pmol of each
primer (TIB MOLBIOL). The PCR comprised an initial
denaturation step (95uC for 5 min), 35 cycles (denaturation at
94uC for 30 sec, primer annealing at 60uC for 30 sec, extension at
72uC for 30 sec) and a final extension step (72uC for 10 min). The
PCR products were purified using the QIAquick PCR Purification
Kit (Qiagen) and sequenced by a commercial sequencing company
(Sequiserve, Vaterstetten, Germany). All sequences of primers and
FRET probes used for genotyping and for sequence analysis are
given in Tables S1 and S2.
Genotyping of NOD2, IL23R and ATG16L1 variants
For analysis of potential epistatic interactions, the genotypes of
gene variants in NOD2, IL23R and ATG16L1 were available from
previous studies for all patients and controls analyzed
[11,27,32,33,34,35,36]. Genotyping of the NOD2 variants
p.Arg702Trp (rs2066844), p.Gly908Arg (rs2066847), and
p.Leu1007fsX1008 (rs2066847) was performed as described
previously (primer sequences available on request) [34]. The 10
IL23R SNPs (rs1004819, rs7517847, rs10489629, rs2201841,
rs11465804, rs11209026=p.Arg381Gln, rs1343151, rs10889677,
rs11209032, rs1495965) and nine ATG16L1 SNPs (rs13412102,
rs12471449, rs6431660, rs1441090, rs2289472, rs2241880
( =T300A), rs2241879, rs3792106, rs4663396) were genotyped
by PCR and melting curve analysis as described previously
[11,35].
Statistical analyses
For evaluation of data, the SPSS 13.0 software (SPSS Inc.,
Chicago, IL, USA) and R-2.13.1 (http://cran.r-project.org) were
used. Each genetic marker was tested for Hardy-Weinberg
equilibrium in the control group. Fisher’s exact test was used for
comparison between categorical variables and Student’s t test was
applied for quantitative variables. All tests were two-tailed and p-
values,0.05 were considered as significant. Odds ratios were
calculated for the minor allele of each SNP. Correction for
multiple testing was performed by Bonferroni correction where
indicated. Haplotype analysis was calculated using the –hap-
logistic command in PLINK (http://pngu.mgh.harvard.edu/
,purcell/plink/), epistasis analysis was performed with the –
epistasis option. LD between SNPs was evaluated using the R-
library genetics. Genotype-phenotype associations were also tested
in R using logistic regression.
Results
The IRGM gene variants are associated with susceptibility
to CD
The allele frequencies of the SNPs rs13371189,
rs10065172= p.Leu105Leu, rs4958847, rs11747270, rs931058
and rs1000113 of all three subgroups (CD, UC, and controls)
were in accordance with the predicted Hardy-Weinberg equilib-
rium and are summarized in Table 2. Overall, our analysis
revealed an association of the IRGM variants rs13371189
(p = 0.02, OR 1.31 [95% CI 1.05–1.65]), rs10065172= p.Leu105-
Leu (p = 0.016, OR 1.33 [95% CI 1.06–1.66]) and rs1000113
(p = 0.047, OR 1.27 [95% CI 1.01–1.61]) with the susceptibility to
CD. Similar to previous studies, rs13371189 and
rs10065172= p.Leu105Leu were in perfect linkage disequilibrium
(r2<1.0) in all three subgroups (CD, UC, controls; Tables S3, S4,
S5). Strong linkage disequilibrium was also shown for these two
SNPs with the third CD-associated IRGM SNP rs1000113 (Tables
S3, S4, S5). With exception of rs11747270, none of the genotyped
IRGM SNPs was associated with UC susceptibility (Table 2).
IRGM haplotype analysis
Next, we performed a detailed haplotype analysis investigating
the role of IRGM haplotypes on CD and UC susceptibility. As
demonstrated in tables 3 and 4, several IRGM haplotypes
demonstrated an association with CD and UC susceptibility. In
CD, the strongest associations were found for haplotypes
IRGM Variants in IBD Susceptibility
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Table 3. Haplotypes of IRGM SNPs in CD case-control sample and omnibus p-values for association with CD susceptibility.
Haplotype combination Haplotype Haplotype frequency P-value OR (95% CI)
rs13361189-rs4958847 CA 0.09 2.3661022 1.31 [1.04–1.65]
TA 0.04 3.6061021 0.85 [0.60–1.20]
TG 0.87 1.3661021 0.86 [0.71–1.05]
rs13361189-rs1000113 CT 0.09 2.9661022 1.30 [1.03–1.65]
TC 0.91 1.9261022 0.76 [0.60–0.96]
rs13361189-rs11747270 CG 0.06 2.7661021 1.19 [0.87–1.63]
CA 0.02 8.3361021 0.95 [0.60–1.50]
TA 0.92 5.3161021 0.92 [0.71–1.20]
rs13361189-rs931058 CT 0.07 1.5561021 1.21 [0.93–1.57]
TT 0.01 4.4961021 0.80 [0.45–1.42]
CA 0.02 2.1461022 1.72 [1.08–2.73]
TA 0.90 4.9061022 0.81 [0.65–1.00]
rs4958847-rs1000113 AT 0.09 3.9361021 1.28 [1.01–1.62]
AC 0.04 6.2761021 0.92 [0.67–1.27]
GC 0.87 1.6761021 0.87 [0.72–1.06]
rs4958847-rs11747270 AG 0.06 3.1361021 1.17 [0.86–1.59]
AA 0.06 5.1661021 0.91 [0.68–1.21]
GA 0.88 8.9461021 0.99 [0.79–1.23]
rs4958847-rs931058 AT 0.07 1.9561021 1.19 [0.91–1.55]
GT 0.01 5.2261021 0.82 [0.45–1.49]
AA 0.06 4.4461021 1.12 [0.84–1.50]
GA 0.86 2.2361021 0.89 [0.74–1.07]
rs1000113-rs11747270 TG 0.05 2.8761021 1.19 [0.86–1.64]
TA 0.02 4.0861021 0.82 [0.51–1.31]
CA 0.92 7.8161021 0.96 [0.74–1.26]
rs1000113-rs931058 TT 0.07 1.3561021 1.22 [0.94–1.58]
CT 0.01 2.4461021 0.71 [0.40–1.26]
TA 0.02 9.4361021 1.60 [0.92–2.77]
CA 0.90 1.3961021 0.85 [0.68–1.06]
rs11747270-rs931058 GT 0.04 4.9661021 1.13 [0.79–1.61]
AT 0.03 7.9861022 0.70 [0.47–1.04]
GA 0.01 5.4261021 1.21 [0.66–2.23]
AA 0.91 6.8761021 1.05 [0.83–1.33]
rs13361189-rs4958847-rs1000113 CAT 0.08 2.8361022 1.31 [1.03–1.67]
TAC 0.04 3.9461021 0.86 [0.61–1.22]
TGC 0.87 1.3061021 0.86 [0.71–1.05]
rs13361189-rs4958847-rs11747270 CAG 0.06 1.9761022 1.40 [1.06–1.86]
CAA 0.03 4.4261021 1.19 [0.76–1.85]
TAA 0.04 3.6161021 0.85 [0.60–1.20]
TGA 0.87 1.5861021 0.87 [0.72–1.06]
rs13361189-rs4958847-rs931058 CAT 0.07 1.4761021 1.21 [0.94–1.57]
TGT 0.01 4.7361021 0.81 [0.45–1.45]
CAA 0.02 3.4861022 1.66 [1.04–2.66]
TAA 0.04 3.7861021 0.86 [0.61–1.21]
TGA 0.86 2.1061021 0.89 [0.74–1.07]
rs13361189-rs1000113-rs11747270 CTG 0.06 1.4761022 1.44 [1.07–1.93]
CTA 0.03 7.5461021 1.07 [0.70–1.64]
TCA 0.91 2.9361022 0.78 [0.62–0.97]
rs13361189-rs1000113-rs931058 CTT 0.07 1.4961021 1.21 [0.93–1.57]
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Table 3. Cont.
Haplotype combination Haplotype Haplotype frequency P-value OR (95% CI)
TCT 0.01 2.9561021 0.73 [0.41–1.31]
CTA 0.01 4.8961022 1.76 [1.00–3.09]
TCA 0.89 7.3761021 0.82 [0.66–1.02]
CGT 0.05 5.3461022 1.37 [1.00–1.89]
CAT 0.02 7.9961021 0.94 [0.57–1.53]
TAT 0.01 3.4361021 0.75 [0.42–1.35]
CGA 0.02 9.9361022 1.62 [0.91–2.87]
TAA 0.89 7.4661022 0.82 [0.67–1.02]
rs4958847-rs1000113-rs11747270 ATG 0.06 1.6661022 1.43 [1.07–1.92]
ATA 0.03 8.6561021 1.04 [0.66–1.63]
ACA 0.04 6.7061021 0.93 [0.67–1.30]
GCA 0.87 1.8861021 0.88 [0.72–1.07]
rs4958847-rs1000113-rs931058 ATT 0.07 1.3461021 1.22 [0.94–1.58]
GCT 0.01 3.3561021 0.75 [0.41–1.35]
ATA 0.02 9.3661022 1.60 [0.92–2.77]
ACA 0.04 7.2361021 0.94 [0.69–1.30]
GCA 0.86 2.9461021 0.91 [0.75–1.09]
AGT 0.05 4.8761022 1.38 [1.00–1.90]
AAT 0.02 5.8761021 0.87[0.53–1.44]
GAT 0.01 4.6461021 0.80 [0.44–1.45]
AGA 0.01 3.3961021 1.36 [0.72–2.55]
AAA 0.04 7.0261021 1.07 [0.76–1.51]
GAA 0.86 2.5961021 0.90 [0.75–1.08]
rs1000113-rs11747270-rs931058 TGT 0.05 4.3861022 1.39 [1.01–1.91]
TAT 0.02 7.8361021 0.93 [0.57–1.53]
CAT 0.01 2.5161021 0.71 [0.40–1.27]
TGA 0.01 1.5161021 1.66 [0.83–3.32]
CAA 0.90 1.7761021 0.86 [0.69–1.07]
rs13361189-rs4958847-rs1000113-rs11747270 CATG 0.06 1.8361022 1.42 [1.06–1.90]
CATA 0.03 7.2461021 1.08 [0.70–1.65]
TACA 0.04 3.9561021 0.86 [0.61–1.22]
TGCA 0.87 1.6961021 0.87 [0.72–1.06]
rs13361189-rs4958847-rs1000113-rs931058 CATT 0.07 1.4561021 1.21 [0.94–1.56]
TGCT 0.01 3.4961021 0.76 [0.42–1.36]
CATA 0.01 5.1461022 1.75 [1.00–3.07]
TACA 0.04 3.9361021 0.86 [0.61–1.22]
TGCA 0.86 2.6161021 0.90 [0.75–1.08]
CAGT 0.05 6.4461022 1.35 [0.98–1.86]
CAAT 0.02 7.9961021 0.94 [0.57–1.54]
TGAT 0.01 3.6561021 0.76 [0.42–1.37]
CAGA 0.01 1.3561021 1.58 [0.87–2.88]
TAAA 0.03 4.2261021 0.87 [0.61–1.23]
TGAA 0.86 2.6261021 0.90 [0.75–1.08]
CTGT 0.05 5.0661022 1.38 [1.00–1.91]
CTAT 0.02 8.5761021 0.96 [0.58–1.57]
TCAT 0.01 2.8761021 0.73 [0.41–1.31]
CTGA 0.01 1.0961021 1.78 [0.88–3.61]
TCAA 0.89 9.4661022 0.83 [0.67–1.03]
rs4958847-rs1000113-rs11747270-rs931058 ATGT 0.05 4.7461022 1.39 [1.00–1.92]
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containing at least one of the most strongly CD-associated SNP
rs13361189 or rs10065172 (Table 3), while in UC, the strongest
association was found for rs11747270-rs931058 (omnibus p-value
1.5761022) (Table 4). However, given the large number of
haplotypes analyzed, none of these associations withstood
Bonferroni correction for multiple testing.
Genotype-phenotype analysis
We further investigated whether IRGM SNPs are associated
with certain phenotypic characteristics in IBD patients. Based on
the Montreal classification of IBD, the phenotypic data of IBD
patients were analyzed for anatomic localization. However, none
of the IRGM SNPs investigated were associated with specific
disease localization in CD (Table S6) or UC (Table S7). Moreover,
a detailed genotype-phenotype analysis in CD patients of the
exonic synonymous SNP rs10065172= p.Leu105Leu, which was
in linkage disequilibrium with rs13361189 and with the previously
identified 20-kb deletion polymorphism immediately upstream of
IRGM (r2 = 1.0), did not reveal any significant associations with the
CD phenotype (Table S8).
Analysis for epistasis of IRGM with other major CD
susceptibility genes
Finally, we analyzed potential evidence for gene-gene interac-
tions of IRGM variants with other CD susceptibility genes such as
variants in the NOD2, IL23R and ATG16L1 gene including their
effect on CD susceptibility. Interestingly, there was evidence for
weak gene-gene-interaction between several SNPs of the two
autophagy genes IRGM and ATG16L1 (ATG16L1 rs12471449,
ATG16L1 rs1441090, ATG16L1 rs4663396), which, however, did
not remain significant after Bonferroni correction (Table 5). The
odds ratios of gene-gene interactions, which were significant before
Bonferroni correction, are given in Table 6. There was no epistasis
between IRGM and the other two major CD susceptibility genes
NOD2 and IL23R.
Discussion
This study represents a detailed analysis of IRGM gene variants
regarding their role in the susceptibility and phenotype of IBD in a
large cohort of more than 2000 Caucasian individuals. In line with
previous GWAS and replication studies [12,13,14,15,16,17,18,19],
our results confirm an association of the IRGM variant rs13371189
with CD susceptibility. A detailed functional study identified a
deletion polymorphism directly upstream of the IRGM locus as a
candidate SNP to explain the CD association at this locus [22],
affecting the tissue-specific expression level of IRGM [37]. This
20-kb deletion polymorphism is in perfect linkage disequilibrium
(r2 = 1.0) with SNP rs13361189, therefore implicating that
rs13361189 is a proxy for this deletion polymorphism.
Similar to the study by McCarroll et al. [22], we demonstrate
that the common exonic synonymous SNP
rs10065172= p.Leu105Leu is in linkage disequilibrium with
rs13361189 and therefore also with the previously identified 20-
kb deletion polymorphism. The exonic SNP rs10065172
(c.313C.T) has been previously classified as non-causative given
the absence of an alteration in the IRGM protein sequence or
splice sites, although this view is challenged by the results of a very
recent study [21]. The study by Brest et al. demonstrated that a
family of microRNAs (miRNAs), miR-196, is overexpressed in the
inflamed intestinal epithelium of CD patients and downregulates
the IRGM protective variant (c.313C) but not the CD-associated
allele (c.313T) [21]. The same study demonstrated that the
resulting loss of tight regulation of IRGM expression compromises
the control of the intracellular replication of CD-associated
adherent invasive Escherichia coli (AIEC) by affecting the efficacy
of bacterial phagocytosis (xenophagy) [21]. Therefore, Brest et al.
[21] suggest the synonymous SNP rs10065172 (c.313C.T) as a
likely causal variant. rs10065172 has been also shown to be
associated with susceptibility to tuberculosis [38] which is of
interest, given evidence that certain mycobacteria may play a role
in the pathogenesis of CD. Moreover, a functional study
demonstrated that IRGM induces autophagy to eliminate
intracellular mycobacteria [23].
Overall, the association signal of IRGM with CD found in our
study was considerably weaker than that shown by us for the other
autophagy gene ATG16L1 in a similar sized cohort [11]. Similarly,
the recent CD meta-analyses showed a stronger association signal
for ATG16L1 than for IRGM [5]. Anderson et al. performed a very
large meta-analysis of CD and UC associated susceptibility loci
[6]. In this analysis, the CD case-control cohort included n= 6,333
CD patients and n= 15,056 controls, while the UC case-control
cohort consisted of n= 6,687 UC patients and 19,718 controls [6].
In this large meta-analysis, they demonstrated that the IRGM SNP
Table 3. Cont.
Haplotype combination Haplotype Haplotype frequency P-value OR (95% CI)
ATAT 0.02 8.1361021 0.94 [0.57–1.55]
GCAT 0.01 2.8561021 0.73 [0.40–1.31]
ATGA 0.01 1.5861021 1.65 [0.82–3.31]
ACAA 0.04 7.9261021 0.96 [0.68–1.33]
GCAA 0.86 3.1561021 0.91 [0.76–1.09]
rs13361189-rs4958847-rs1000113-rs11747270-rs931058 CATGT 0.05 4.9661022 1.38 [1.00–1.90]
CATAT 0.02 8.6561021 0.96 [0.58–1.57]
TGCAT 0.01 2.9761021 0.73 [0.41–1.31]
CATGA 0.01 1.0761021 1.79 [0.88–3.64]
TACAA 0.04 4.0461021 0.86 [0.61–1.22]
TGCAA 0.86 3.0761021 0.91 [0.76–1.09]
Note: P-values,0.05 are depicted in bold (uncorrected p-values). No association remained significant after Bonferroni correction for multiple testing. rs10065172, which
is in linkage disequilibrium with rs13361189, was excluded from the haplotype analysis.
doi:10.1371/journal.pone.0054338.t003
IRGM Variants in IBD Susceptibility
PLOS ONE | www.plosone.org 7 January 2013 | Volume 8 | Issue 1 | e54338
Table 4. Haplotypes of IRGM SNPs in UC case-control sample and omnibus p-values for association with UC susceptibility.
Haplotype combination Haplo type Haplo type frequency P-value OR (95% CI)
rs13361189-rs4958847 CA 0.09 4.1461021 1.15 [0.82–1.61]
TA 0.04 9.6261022 0.62 [0.35–1.09]
TG 0.87 7.4661021 1.05 [0.78–1.41]
rs13361189-rs1000113 CT 0.09 5.7361021 1.10 [0.79–1.53]
TC 0.91 5.1361021 0.90 [0.65–1.24]
rs13361189-rs11747270 CG 0.06 5.8361022 1.45 [0.99–2.13]
CA 0.02 8.6961022 0.49 [0.22–1.11]
TA 0.92 5.9661021 0.91 [0.64–1.29]
rs13361189-rs931058 CT 0.07 5.3761021 1.12 [0.78–1.60]
TT 0.01 3.2561022 0.11 [0.02–0.83]
CA 0.02 6.6961021 1.16 [0.59–2.29]
TA 0.90 8.1361021 1.04 [0.75–1.44]
rs4958847-rs1000113 AT 0.09 6.5161021 1.08 [0.77–1.51]
AC 0.04 2.6961021 0.76 [0.46–1.24]
GC 0.87 7.4561021 1.05 [0.78–1.41]
rs4958847-rs11747270 AG 0.06 6.1061022 1.44 [0.98–2.11]
AA 0.06 3.2161022 0.59 [0.36–0.96]
GA 0.88 7.2561021 1.06 [0.77–1.47]
rs4958847-rs931058 AT 0.07 6.1061021 1.10 [0.76–1.59]
GT 0.01 5.3461022 0.24 [0.06–1.02]
AA 0.06 3.5061021 0.81 [0.52–1.26]
GA 0.86 3.7961021 1.13 [0.86–1.48]
rs1000113-rs11747270 TG 0.05 1.1961021 1.38 [0.92–2.07]
TA 0.02 4.2561022 0.41 [0.17–0.97]
CA 0.92 7.4661021 0.94 [0.66–1.34]
rs1000113-rs931058 TT 0.07 6.5461021 1.09 [0.75–1.59]
CT 0.01 5.9261022 0.32 [0.10–1.05]
TA 0.02 9.6261021 1.02 [0.45–2.30]
CA 0.90 7.0061021 1.07 [0.76–1.51]
rs11747270-rs931058 GT 0.04 6.5661022 1.49 [0.97–2.28]
AT 0.03 6.3861023 0.34 [0.16–0.74]
GA 0.01 9.2861021 1.04 [1.45–2.42]
AA 0.91 6.7661021 1.08 [0.75–1.55]
rs13361189-rs4958847-rs1000113 CAT 0.08 5.7561021 1.10 [0.79–1.53]
TAC 0.04 1.1561021 0.63 [0.36–1.12]
TGC 0.87 7.1861021 1.05 [0.81–1.37]
rs13361189-rs4958847-rs11747270 CAG 0.06 4.7761022 1.45 [1.00–2.09]
CAA 0.03 1.0261021 0.52 [0.24–1.14]
TAA 0.04 1.0661021 0.63 [0.35–1.10]
TGA 0.87 6.8361021 1.06 [0.80–1.40]
rs13361189-rs4958847-rs931058 CAT 0.07 5.3461021 1.12 [0.78–1.60]
TGT 0.01 4.5461022 0.22 [0.05–0.97]
CAA 0.02 6.0161021 1.21 [0.59–2.47]
TAA 0.04 1.0261021 0.62 [0.35–1.10]
TGA 0.86 3.2261021 1.15 [0.87–1.52]
rs13361189-rs1000113-rs11747270 CTG 0.06 7.4261022 1.42 [0.97–2.09]
CTA 0.03 6.9861022 0.47 [0.20–1.06]
TCA 0.91 6.0861021 0.92 [0.66–1.27]
rs13361189-rs1000113-rs931058 CTT 0.07 6.3461021 1.09 [0.76–1.55]
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Table 4. Cont.
Haplotype combination Haplo type Haplo type frequency P-value OR (95% CI)
TCT 0.01 3.6661022 0.21 [0.05–0.91]
CTA 0.01 7.8961021 1.13 [0.46–2.77]
TCA 0.89 7.9461021 1.04 [0.77–1.40]
CGT 0.05 6.0161022 1.48 [0.98–2.23]
CAT 0.02 9.7461022 0.48 [0.20–1.15]
TAT 0.01 3.1861022 0.14 [0.02–0.84]
CGA 0.02 6.0361021 1.25 [0.54–2.90]
TAA 0.89 7.8561021 1.04 [0.78–1.38]
rs4958847-rs1000113-rs11747270 ATG 0.06 8.3961022 1.40 [0.96–2.05]
ATA 0.03 6.1861022 0.46 [0.20–1.04]
ACA 0.04 1.2261021 0.65 [0.37–1.12]
GCA 0.87 6.5961021 1.07 [0.79–1.44]
rs4958847-rs1000113-rs931058 ATT 0.07 6.4261021 1.09 [0.76–1.57]
GCT 0.01 3.9261022 0.21 [0.05–0.93]
ATA 0.02 9.5861021 1.02 [0.49–2.14]
ACA 0.04 2.3161021 0.73 [0.44–1.22]
GCA 0.86 3.1561021 1.15 [0.88–1.51]
AGT 0.05 6.1861022 1.48 [0.98–2.23]
AAT 0.02 5.2161022 0.40 [0.16–1.01]
GAT 0.01 4.8361022 0.22 [0.05–0.99]
AGA 0.01 6.5261021 1.23 [0.50–3.02]
AAA 0.04 1.8761021 0.70 [0.41–1.19]
GAA 0.86 3.1061021 1.15 [0.88–1.51]
rs1000113-rs11747270-rs931058 TGT 0.05 8.4561022 1.44 [0.95–2.18]
TAT 0.02 6.5961022 0.42 [0.17–1.06]
CAT 0.01 3.4461022 0.21 [0.05–0.89]
TGA 0.01 7.3661021 1.19 [0.43–3.27]
CAA 0.90 7.2161021 1.06 [0.77–1.46]
rs13361189-rs4958847-rs1000113-rs11747270 CATG 0.06 7.9061022 1.41 [0.96–2.07]
CATA 0.03 7.6661022 0.47 [0.21–1.08]
TACA 0.04 1.1461021 0.63 [0.36–1.12]
TGCA 0.87 6.6061021 1.07 [0.79–1.45]
rs13361189-rs4958847-rs1000113-rs931058 CATT 0.07 6.2761021 1.10 [0.75–1.62]
TGCT 0.01 4.1661022 0.22 [0.05–0.94]
CATA 0.01 8.0161021 1.12 [0.46–2.70]
TACA 0.04 1.1561021 0.63 [0.36–1.12]
TGCA 0.86 2.9361021 1.16 [0.88–1.53]
CAGT 0.05 6.4161022 1.47 [0.98–2.21]
CAAT 0.02 7.2261022 0.43 [0.17–1.08]
TGAT 0.01 4.3161022 0.23 [0.05–0.96]
CAGA 0.01 4.8461021 1.35 [0.58–3.13]
TAAA 0.03 1.1861021 0.63 [0.36–1.12]
TGAA 0.86 2.9861021 1.16 [0.88–1.53]
CTGT 0.05 8.2461022 1.45 [0.95–2.20]
CTAT 0.02 7.5261022 0.44 [0.17–1.09]
TCAT 0.01 3.6961022 0.21 [0.05–0.91]
CTGA 0.01 6.4261021 1.28 [0.45–3.63]
TCAA 0.89 7.2361021 1.06 [0.77–1.46]
rs4958847-rs1000113-rs11747270-rs931058 ATGT 0.05 8.4161022 1.44 [0.95–2.18]
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rs7714584 is associated with both CD (p= 7.76610219; OR 1.37,
95% CI 1.28–1.47) and UC (p= 3.9561024; OR 1.14, 95% CI
1.06–1.22) [6]. However, the authors defined only SNPs with p-
values of ,161024 to be significantly associated with both CD
and UC and therefore included IRGM not in the list of
susceptibility loci shared between CD and UC [6]. In addition,
the meta-analysis of Palomino-Morales et al. demonstrated also an
association of two IRGM SNPs with UC (rs13361189 p=0.0069,
Table 4. Cont.
Haplotype combination Haplo type Haplo type frequency P-value OR (95% CI)
ATAT 0.02 7.5161022 0.44 [0.17–1.09]
GCAT 0.01 3.5561022 0.21 [0.05–0.90]
ATGA 0.01 7.4761021 1.19 [0.41–3.43]
ACAA 0.04 1.4361021 0.66 [0.38–1.15]
GCAA 0.86 2.7661021 1.17 [0.88–1.55]
rs13361189-rs4958847-rs1000113-rs11747270-rs931058 CATGT 0.05 7.9061022 1.45 [0.96–2.19]
CATAT 0.02 7.6761022 0.44 [0.17–1.09]
TGCAT 0.01 3.7661022 0.21 [0.05–0.92]
CATGA 0.01 6.3761021 1.28 [0.46–3.57]
TACAA 0.04 1.1861021 0.64 [0.36–1.12]
TGCAA 0.86 2.6261021 1.17 [0.89–1.54]
Note: SNPs in CD case-control sample and omnibus p-values for association with CD susceptibility. P-values,0.05 are depicted in bold (uncorrected p-values). No
association remained significant after Bonferroni correction for multiple testing. rs10065172, which is in linkage disequilibrium with rs13361189, was excluded from the
haplotype analysis.
doi:10.1371/journal.pone.0054338.t004
Table 5. Analysis for gene-gene interaction (epistasis) of IRGM SNPs with NOD2, ATGT16L1, and IL23R gene variants regarding CD
susceptibility.
rs13361189 rs4958847 rs1000113 rs11747270 rs931058
NOD2 rs2066844 = p.Arg702Trp 8.1061021 5.0061021 8.7561021 8.2461021 7.8761021
NOD2 rs2066845 = p.Gly908Arg 2.0761021 2.3761021 1.5561021 5.9761021 4.3361021
NOD2 rs2066847 = p.Leu1007fsX1008 9.4361021 9.7061021 9.7261021 6.2661021 8.6561021
ATG16L1 rs13412102 4.1461021 3.4061021 6.2461021 7.4161021 4.5761021
ATG16L1 rs12471449 2.0061022 6.0961022 2.0161022 1.1161021 5.4161023
ATG16L1 rs6431660 8.5361021 8.4261021 8.3861021 4.7761021 7.6461021
ATG16L1 rs1441090 1.2761021 6.7461021 4.4561022 1.3561021 2.8561020
ATG16L1 rs2289472 9.5361021 6.5861021 8.6361021 5.3461021 6.7961021
ATG16L1 rs2241880 6.1561021 5.8861021 6.0161021 4.7261021 9.6261021
ATG16L1 rs2241879 9.2461021 7.9461021 9.7161021 6.1961021 7.1361021
ATG16L1 rs3792106 7.1961021 9.0861021 5.5461021 4.5361021 9.2961021
ATG16L1 rs4663396 1.1961022 2.8961023 1.9161022 1.9461021 2.1661022
IL23R rs1004819 6.7561021 2.6161021 5.0161021 7.0561021 6.5261021
IL23R rs7517847 1.3661021 3.3661021 1.3361021 4.3061021 8.0561022
IL23R rs10489629 6.6061021 9.7461021 9.4961021 8.7361022 2.7461021
IL23R rs2201841 2.6661021 5.5961022 8.6061022 5.7261022 2.5461021
IL23R rs11465804 6.0461022 1.0961021 1.9861021 9.8561021 1.7661021
IL23R rs11209026 = p.Arg381Gln 1.9361021 1.6261021 3.9261021 6.8461021 2.6061021
IL23R rs1343151 7.7061021 3.6461021 9.5761021 3.7161021 9.6961021
IL23R rs10889677 1.6361021 3.5661022 6.4761022 3.2761022 1.7961021
IL23R rs11209032 2.6661021 1.8061021 1.9261021 8.2361022 2.8461021
IL23R rs1495965 8.5461021 4.6661021 6.0061021 1.7961021 9.8661021
Note: p-values for epistasis between NOD2 and ATGT16L1 SNPs and IRGM SNPs in CD case-control sample. P-values,0.05 are depicted in bold. After Bonferroni
correction, none of the associations highlighted in bold remained significant. We excluded rs10065172, which is in linkage disequilibrium with rs13361189, from the
epistasis analysis.
doi:10.1371/journal.pone.0054338.t005
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pooled OR=1.16; rs4958847 p= 0.014, pooled OR=1.13) [14].
Most importantly, a recent very large IBD meta-analysis
comprising 75,000 IBD patients and controls confirmed the IRGM
gene region to be strongly associated with CD (p= 2.94610237)
and to a much lesser degree with UC (p= 0.0025 for the UC
GWAS cohort and p= 1.0561027 for the combined UC
Immunochip and GWAS cohort) [39]. Therefore, based on these
meta-analyses as well as on our results showing a trend for
association with UC for the IRGM SNP rs11747270 (p = 0.084,
OR 1.42 [0.96–2.12] for comparing minor allele frequencies;
p = 0.033, OR 5.34 [1.03–34.64] for comparing genotype
frequencies; Table 2) and associations of several IRGM haplotypes
with UC (p,0.05), IRGM can be regarded to be weakly associated
with UC and as a shared susceptibility gene of both UC and CD,
although it has a much more prominent role in the pathogenesis of
CD.
In addition, we also performed a detailed genotype-phenotype
analysis of IRGM variants in CD and UC patients. In contrast to a
recent study of Latiano et al. [40] demonstrating an association of
IRGM variants with fistulizing CD, our genotype-phenotype
analysis did not reveal any significant association of IRGM variants
with the CD phenotype. We were also unable to confirm an
association with ileal CD found in a previous study of a smaller
CD cohort from New Zealand [18]. Our findings may be related
to the rather weak association signal found for IRGM in the
German CD cohort, although the results of this genotype-
phenotype analysis are consistent with the lack of a well-defined
phenotype in CD patients carrying risk alleles of the other
autophagy gene ATG16L1 [11].
The identification of the two major CD susceptibility genes
ATG16L1 and IRGM involved in autophagy has significantly
strengthened the importance of autophagy and bacterial xeno-
phagy in the complex and multifactorial etiology of IBD.
However, potential epistatic interactions between ATG16L1 and
IRGM have not been investigated in detail so far. We therefore
analyzed epistasis between these two genes, demonstrating a weak
gene-gene-interaction between several SNPs of the two autophagy
genes IRGM and ATG16L1 which, however, did not remain
significant after Bonferroni correction. Given their close functional
relationship, this potential epistasis signal is highly interesting.
Very recently, the largest IBD meta-analysis published so far
(including 75,000 IBD patients and controls) was made publicly
available [39]. Part of this meta-analysis was an epistasis analysis in
IBD, UC and CD datasets of the Immunochip study. While the
analyses of the CD and UC subsets were inconclusive, the results
for the analysis with IBD showed only one suggestive result
between SNPs near SLC7A10 (rs17694108) and IL2RA
(rs12722515) with a p-value of 3.2661025 [39]. Therefore, the
weak gene-gene interaction found between IRGM and ATG16L1
regarding CD susceptibility in our study, which was not significant
after Bonferroni correction, could not been replicated on a
significant level in this very large CD cohort. Thus, it is unlikely
that epistasis between the two major autophagy genes contributes
significantly to CD susceptibility.
There is increasing evidence for important intersections of
autophagy and intracellular bacterial sensing (demonstrated by the
importance of NOD2 in autophagy induction [41,42]) in the
pathogenesis of IBD. Moreover, recent studies identified a new
pathway closely linked to autophagy and innate immunity, which
is characterized by an unfolded protein response, stimulated by
endoplasmic reticulum (ER) stress due to the accumulation of
misfolded proteins. Several genes involved in ER stress, including
XBP1 and ORMDL3 have been linked to the IBD pathogenesis on
a genetic level [43,44]. Interestingly, ATG16L1, NOD2, and XBP1
have been also demonstrated to affect the function of Paneth cells
[43,45,46], suggesting a central role for this cell type in the
development of IBD.
These recent findings are in line with raising evidence that
NOD2 is involved in regulation of autophagy. Dendritic cells from
CD patients expressing CD-associated NOD2 or ATG16L1 variants
were shown to be defective in autophagy induction, bacterial
trafficking and antigen presentation [41]. Most interestingly, a
recent study demonstrated that the intracellular sensors NOD1
and NOD2 are critical for the autophagic response to invasive
bacteria by recruiting the autophagy protein ATG16L1 to the
plasma membrane at the bacterial entry site [42]. In cells
homozygous for the CD-associated NOD2 frameshift mutation
(p.Leu1007fsX1008), mutant NOD2 failed to recruit ATG16L1 to
the plasma membrane and wrapping of invading bacteria by
autophagosomes was impaired [42]. This is of particular interest,
since we previously demonstrated a very severe stricturing
phenotype in CD patients homozygous for the NOD2
p.Leu1007fsX1008 mutation associated with early disease onset,
ileal stenosis, recurrent need for surgery and increased prevalence
of entero-enteral fistulae [32,33]. However, despite the central
functional role of NOD2 in the induction of autophagic processes,
our study could not demonstrate gene-gene-interactions between
NOD2 and IRGM regarding CD susceptibility. Moreover, we could
not identify significant epistatic interactions between IRGM and
IL23R, the main IBD susceptibility gene involved in Th17
responses. Of interest, a very recent study demonstrated IL23R
variants as susceptibility variants for leprosy and suggested a
potential involvement of IL23R in the autophagocytosis of
mycobacteria involved in the pathogenesis of leprosy [47].
In conclusion, our results confirm IRGM as susceptibility gene
for CD in the German population, while we did not show an
Table 6. Odds ratios (ORs) and 95% CI for the gene-gene interaction (epistasis) found to be significant (before Bonferroni
correction) for CD susceptibility (shown in Table 5).
rs13361189 rs10065172 rs4958847 rs1000113 rs11747270 rs931058
ATG16L1 rs12471449 1.87 [1.10–3.17] 1.92 [1.12–3.30] n.s. 1.91 [1.11–3.29] n.s. 2.21 [1.26–3.87]
ATG16L1 rs1441090 n.s. n.s. n.s. 2.35 [1.02–5.39] n.s. 2.42 [2.00–5.33]
ATG16L1 rs4663396 1.80 [1.14–2.83] 1.76 [1.11–2.78] 1.81 [1.22–2.66] 1.76 [1.10–2.82] n.s. 1.75 [1.09–2.81]
IL23R rs10889677 n.s. n.s. 0.72 [0.54–0.98] n.s. 0.58 [0.35–0.96] n.s.
Note: After Bonferroni correction, significance was lost for all gene-gene interactions shown in this table. rs10065172, which is in linkage disequilibrium with rs13361189,
was excluded from the epistasis analysis.
n.s.: non-significant interactions (not shown).
doi:10.1371/journal.pone.0054338.t006
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association with a specific IBD subphenotype. The strongest
association signals for CD susceptibility were found for
rs13361189 (proxy for the common, 20-kb deletion polymorphism
upstream of IRGM) and the exonic synonymous SNP
rs10065172=p.Leu105Leu, supporting previous functional stud-
ies that these two SNPs may be the causal variants. However, the
strength of the association signal with CD found here was several
log-fold weaker than that demonstrated by us for the second
autophagy gene ATG16L1 [11], suggesting a more important role
for ATG16L1 in the CD pathogenesis. In UC, several IRGM
haplotypes were weakly associated with UC susceptibility. This is
consistent with recent meta-analyses which found weak associa-
tions with UC but very strong disease associations with CD. One
might therefore hypothesize that autophagy genes such as IRGM
and ATG16L1 play a more important role in the susceptibility to
CD than UC. The potential epistasis signal between IRGM and
ATG16L1 regarding CD susceptibility found in this study is highly
interesting but could not been confirmed in a very large recent
IBD meta-analysis [39] arguing against a major role of epistasis
between IRGM and ATG16L1 regarding CD susceptibility.
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